Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases
A Bacterial Bi-functional Peptidoglycan Hydrolase Sheds NOD2 Ligands to Regulate Gut Homeostasis
1 other identifier
observational
600
1 country
1
Brief Summary
Nucleotide-binding oligomerization domain 2 (Nod2) signaling is critical for human health.To figure out the clinical relevance of NOD2 ligands, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 10, 2020
CompletedFirst Submitted
Initial submission to the registry
June 7, 2021
CompletedFirst Posted
Study publicly available on registry
June 14, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 10, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2023
CompletedJune 14, 2021
June 1, 2021
3.1 years
June 7, 2021
June 10, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
NOD2 ligands in fecal and plasma
detected using targeted metabolomics (LC-MS-MS methods) and NOD2-transfected cells co-expressing NF-κB luciferase reporters
baseline
Study Arms (5)
Crohn's disease
The fecal and plasma were collected
Ulcerative colitis
The fecal and plasma were collected
Diabetes mellitus, type 2
The fecal and plasma were collected
Atherosclerotic cardiovascular disease
The fecal and plasma were collected
Colorectal cancer
The fecal and plasma were collected
Interventions
Observational studies, no intervention
Eligibility Criteria
All the patients with IBD, CRC, ACVD or DM2 hospitalized in Zhujiang hospital will be eligible to be enrolled. Also, their age- and sex- matched healthy controls making a physical examination in Zhujiang hospital will be eligible to be enrolled
You may qualify if:
- Males or females at least 18-70 years old.
- Patient able to give informed consent.
- Patient with biopsy-proven CRC
- Patient with biopsy-proven Crohn's disease (CD) or ulcerative colitis(UC), in the active phase.
- patients with clinical diagnosed DM2
- patients with ACVD:coronary angiography more than 50% stenosis in single or multiple vessels.
- The age- and sex- matched health controls for each patient.
You may not qualify if:
- Use antibiotics or probiotics within the last 2 weeks.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zhujiang Hospitallead
- National Natural Science Foundation of Chinacollaborator
Study Sites (1)
Zhujiang hospital
Guangzhou, Guangdong, 510000, China
Related Publications (1)
Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol. 2014 Jan;14(1):9-23. doi: 10.1038/nri3565. Epub 2013 Dec 13.
PMID: 24336102BACKGROUND
Biospecimen
Fecal, Plasma
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Hongwei Zhou, professor
Zhujiang Hospital, Guangzhou, Guangdong
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Proffessor
Study Record Dates
First Submitted
June 7, 2021
First Posted
June 14, 2021
Study Start
May 10, 2020
Primary Completion
June 10, 2023
Study Completion
August 15, 2023
Last Updated
June 14, 2021
Record last verified: 2021-06
Data Sharing
- IPD Sharing
- Will not share